Holen Sie sich die Stockscreener-App
46.73
0.39%
0.18
Handel nachbörslich:
46.73
Schlusskurs vom Vortag:
$46.55
Offen:
$46.62
24-Stunden-Volumen:
680.31K
Relative Volume:
0.53
Marktkapitalisierung:
$4.43B
Einnahmen:
$4.72M
Nettoeinkommen (Verlust:
$-277.91M
KGV:
-12.53
EPS:
-3.73
Netto-Cashflow:
$-203.56M
1W Leistung:
-2.56%
1M Leistung:
+3.82%
6M Leistung:
+58.73%
1J Leistung:
-9.35%
1-Tages-Spanne:
$45.51
$47.05
1-Wochen-Bereich:
$45.51
$48.25
52-Wochen-Spanne:
$24.10
$53.55
Crinetics Pharmaceuticals Inc Stock (CRNX) Company Profile
Firmenname
Crinetics Pharmaceuticals Inc
Sektor
Branche
Telefon
858-450-6464
Adresse
6055 LUSK BLVD., SAN DIEGO, CA
Vergleichen Sie CRNX mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
CRNX
Crinetics Pharmaceuticals Inc
|
46.73 | 4.42B | 4.72M | -277.91M | -203.56M | -3.73 |
|
VRTX
Vertex Pharmaceuticals Inc
|
452.13 | 115.03B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
776.31 | 81.12B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
400.17 | 52.54B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
839.99 | 51.78B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
177.12 | 37.12B | 447.02M | -1.18B | -906.14M | -6.1812 |
Crinetics Pharmaceuticals Inc Stock (CRNX) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-07-10 | Eingeleitet | Goldman | Neutral |
| 2025-03-25 | Eingeleitet | Stifel | Buy |
| 2025-02-11 | Eingeleitet | TD Cowen | Buy |
| 2025-02-04 | Eingeleitet | Wolfe Research | Peer Perform |
| 2025-01-22 | Hochstufung | Jefferies | Hold → Buy |
| 2024-03-06 | Eingeleitet | Citigroup | Buy |
| 2024-01-16 | Eingeleitet | Morgan Stanley | Overweight |
| 2023-12-21 | Eingeleitet | Jefferies | Hold |
| 2023-11-20 | Fortgesetzt | JP Morgan | Overweight |
| 2023-10-24 | Fortgesetzt | Cantor Fitzgerald | Overweight |
| 2023-08-31 | Eingeleitet | Oppenheimer | Outperform |
| 2023-04-24 | Eingeleitet | Piper Sandler | Overweight |
| 2023-03-30 | Eingeleitet | Robert W. Baird | Outperform |
| 2021-11-30 | Eingeleitet | JMP Securities | Mkt Outperform |
| 2021-11-23 | Eingeleitet | Evercore ISI | Outperform |
| 2021-06-18 | Hochstufung | JP Morgan | Neutral → Overweight |
| 2019-12-23 | Eingeleitet | ROTH Capital | Buy |
| 2019-02-14 | Eingeleitet | H.C. Wainwright | Buy |
| 2018-08-13 | Eingeleitet | JP Morgan | Neutral |
| 2018-08-13 | Eingeleitet | Leerink Partners | Outperform |
| 2018-08-13 | Eingeleitet | Piper Jaffray | Overweight |
Alle ansehen
Crinetics Pharmaceuticals Inc Aktie (CRNX) Neueste Nachrichten
Crinetics to host conference call on paltusotine and atumelnant data By Investing.com - Investing.com Nigeria
Crinetics to host conference call on paltusotine and atumelnant data - Investing.com
Crinetics Pharmaceuticals to Host Conference Call on January 5, 2026, for PALSONIFY™ Update and Phase 2 Trial Results of Atumelnant - Quiver Quantitative
Crinetics Pharmaceuticals to Provide PALSONIFY Business - GlobeNewswire
Avoiding Lag: Real-Time Signals in (CRNX) Movement - Stock Traders Daily
Crinetics Pharmaceuticals (NASDAQ:CRNX) Upgraded at Wall Street Zen - MarketBeat
Stifel Initiates Coverage of Crinetics Pharmaceuticals (CRNX) with Buy Recommendation - MSN
Crinetics Pharmaceuticals (CRNX) poised for transformational growth in 2026: Piper Sandler - MSN
Moody Aldrich Partners LLC Trims Position in Crinetics Pharmaceuticals, Inc. $CRNX - MarketBeat
Investors in Crinetics Pharmaceuticals (NASDAQ:CRNX) Have Seen Impressive Returns of 234% Over the Past Five Years - 富途牛牛
Crinetics Pharmaceuticals Earnings Notes - Trefis
Aug Macro: Will Crinetics Pharmaceuticals Inc stock outperform growth indexesMarket Activity Report & High Accuracy Investment Entry Signals - moha.gov.vn
174,077 Shares in Crinetics Pharmaceuticals, Inc. $CRNX Purchased by Rice Hall James & Associates LLC - MarketBeat
(CRNX) Risk Channels and Responsive Allocation - Stock Traders Daily
Crinetics Pharmaceuticals (CRNX): Assessing Valuation After a 36% Three-Month Share Price Rebound - Sahm
Crinetics Pharmaceuticals (FRA:6Z4) EV-to-OCF : -9.65 (As of Dec. 23, 2025) - GuruFocus
Squarepoint Ops LLC Has $1.21 Million Stake in Crinetics Pharmaceuticals, Inc. $CRNX - MarketBeat
CEO Change: Will ZVRA stock split again soon2025 Momentum Check & Verified Momentum Watchlists - moha.gov.vn
Will Crinetics Pharmaceuticals Inc. stock benefit from green energy trendsWeekly Stock Recap & Free Weekly Watchlist of Top Performers - Улправда
Why Crinetics Pharmaceuticals Inc. stock is a value investor pickMarket Sentiment Summary & Weekly Top Gainers Alerts - Улправда
Will Crinetics Pharmaceuticals Inc. stock recover faster than peersRecession Risk & Free Fast Gain Swing Trade Alerts - Улправда
Is Crinetics Pharmaceuticals Inc. stock attractive for hedge fundsLayoff News & Fast Exit and Entry Strategy Plans - Улправда
What risks investors should watch in Crinetics Pharmaceuticals Inc. stockMarket Sentiment Report & Fast Entry Momentum Trade Alerts - Улправда
Aug Volume: Will Crinetics Pharmaceuticals Inc. stock benefit from green energy trends2025 Stock Rankings & Accurate Buy Signal Alerts - Улправда
Does Crinetics Pharmaceuticals Inc. stock trade at a discount to peersJuly 2025 Intraday Action & Consistent Profit Focused Trading Strategies - DonanımHaber
Is Crinetics Pharmaceuticals Inc. stock overvalued by current metricsWeekly Profit Analysis & Risk Controlled Stock Pick Alerts - DonanımHaber
Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX) Receives Consensus Rating of "Moderate Buy" from Brokerages - MarketBeat
Can Crinetics Pharmaceuticals Inc. (6Z4) stock sustain revenue momentumJuly 2025 Retail & Step-by-Step Trade Execution Guides - DonanımHaber
Crinetics Pharmaceuticals CEO Scott Struthers to Present at 44th Annual J.P. Morgan Healthcare Conference - Quiver Quantitative
Crinetics Pharmaceuticals to Participate in The 44th Annual J.P. Morgan Healthcare Conference - The Manila Times
Crinetics Pharmaceuticals (NASDAQ:CRNX) Stock Price Down 7.9%Here's Why - MarketBeat
Crinetics Pharmaceuticals (CRNX) Stock Drops After CMO Departure Filing: Latest News, Analyst Forecasts, and What’s Next (Dec. 18, 2025) - ts2.tech
Crinetics Pharmaceuticals stock falls after CMO departure announcement By Investing.com - Investing.com South Africa
Crinetics Pharmaceuticals stock falls after CMO departure announcement - Investing.com
Crinetics Pharmaceuticals Shares Fall After Chief Medical, Development Officer Steps Down - marketscreener.com
Why Crinetics Pharmaceuticals Shares Are Sinking Today - TipRanks
How Crinetics Pharmaceuticals Inc. stock trades during market volatilityEarnings Miss & Technical Confirmation Trade Alerts - Улправда
[8-K] Crinetics Pharmaceuticals, Inc. Reports Material Event | CRNX SEC FilingForm 8-K - Stock Titan
Crinetics Pharmaceuticals, Inc. Announces Resignation of Dana Pizzuti as Chief Medical and Development Officer, Effective from December 31, 2025 - marketscreener.com
What is HC Wainwright's Estimate for CRNX FY2025 Earnings? - MarketBeat
Sanders Morris Harris LLC Takes Position in Crinetics Pharmaceuticals, Inc. $CRNX - MarketBeat
What is HC Wainwright's Estimate for CRNX FY2028 Earnings? - MarketBeat
Will Crinetics’ (CRNX) First SST2 NDC Trial and Atumelnant Milestone Reframe Its Pipeline Narrative? - simplywall.st
Crinetics Pharmaceuticals Inc (CRNX) - MSN
CRNX stock touches 52-week low at $35.47 amid market shifts - MSN
Does Crinetics Pharmaceuticals Still Offer Value After Its Recent Share Price Rebound? - Yahoo Finance
Trading the Move, Not the Narrative: (CRNX) Edition - news.stocktradersdaily.com
Crinetics Pharmaceuticals (CRNX) Valuation Check After First-Patient Dosing in New SST2 Tumor Trial - Sahm
Crinetics Announces First Patient Dosed in Pivotal Adult Trial of Atumelnant in Congenital Adrenal Hyperplasia (CAH) - Koreabizwire
Crinetics Pharmaceuticals Doses First Patient in Phase 3 Trial of Atumelnant for Classic Congenital Adrenal Hyperplasia - Quiver Quantitative
Crinetics Announces First Patient Dosed in Pivotal Adult Trial of Atumelnant in Congenital ... - Enidnews.com
Finanzdaten der Crinetics Pharmaceuticals Inc-Aktie (CRNX)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.57%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):